ASH 2018 | The current treatment landscape for CLL
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of the Barts Cancer Institute, London, UK, presents an overview of the updated results of the Phase III MURANO study (NCT02005471), specifically the impact of peripheral blood measurable residual disease (MRD) on long-term clinical outcomes following venetoclax plus rituximab (VenR) vs. bendamustine plus rituximab (BR) in chronic lymphocytic leukemia (CLL) patients. Prof. Gribben also discusses several studies evaluating the use of CAR T-cells in CLL, with notable efficacy and safety results for CD19-directed JCAR014 alone or in combination with ibrutinib for treating relapsed/refractory CLL.
Get great new content delivered to your inboxSign up